Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
Ezra E.W. Cohen(Moores Cancer Center), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Nicolas Mach(University of Geneva), Barbara Burtness(Yale University), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ranee Mehra(University of Maryland, Baltimore), Lisa Licitra(University of Milan), Christophe Le Tourneau(Institut Curie), José Dinis(Instituto Português de Oncologia Francisco Gentil), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Ainara Soria(Hospital Universitario Ramón y Cajal), Alba Tuozzo(Merck & Co., Inc., Rahway, NJ, USA (United States)), J-P. Machiels(Cliniques Universitaires Saint-Luc), M-J. Ahn(Samsung Medical Center), Y. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 90
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856